Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps

Benzinga_recent_news

Feb 20

Takeda Pharmaceutical Co Ltd (NYSE:TAK) shares are down on Friday morning as the company is reportedly demonstrating positive Phase 3 data for its drug Entyvio. This news comes as the broader market ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612938922"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612938922\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612938922?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/20/Takeda-Pharmaceutical-Company.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-02-20 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612938922","market":"sh","top_or_hot":-1,"title":"Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps","media":"Benzinga_recent_news","content":"<div>\n<p>Takeda Pharmaceutical Co Ltd (NYSE:TAK) shares are down on Friday morning as the company is reportedly demonstrating positive Phase 3 data for its drug Entyvio.\nThis news comes as the broader market ...</p>\n\n<a href=\"https://www.benzinga.com/markets/large-cap/26/02/50751295/takeda-shares-down-after-entyvio-shows-strong-results-in-ulcerative-colitis-trial-in-children-shows-potential-to-address-treatment-gaps\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-20 23:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/large-cap/26/02/50751295/takeda-shares-down-after-entyvio-shows-strong-results-in-ulcerative-colitis-trial-in-children-shows-potential-to-address-treatment-gaps><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Takeda Pharmaceutical Co Ltd (NYSE:TAK) shares are down on Friday morning as the company is reportedly demonstrating positive Phase 3 data for its drug Entyvio.\nThis news comes as the broader market ...</p>\n\n<a href=\"https://www.benzinga.com/markets/large-cap/26/02/50751295/takeda-shares-down-after-entyvio-shows-strong-results-in-ulcerative-colitis-trial-in-children-shows-potential-to-address-treatment-gaps\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://www.benzinga.com/markets/large-cap/26/02/50751295/takeda-shares-down-after-entyvio-shows-strong-results-in-ulcerative-colitis-trial-in-children-shows-potential-to-address-treatment-gaps","article_id":"2612938922","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/20/Takeda-Pharmaceutical-Company.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/large-cap/26/02/50751295/takeda-shares-down-after-entyvio-shows-strong-results-in-ulcerative-colitis-trial-in-children-shows-potential-to-address-treatment-gaps","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612938922","pubTimestamp":1771600620,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Takeda shares are down slightly on Friday morning after positive Phase 3 Entyvio data show strong remission rates in ulcerative colitis trial.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK4007":"制药","BK4217":"自存仓储房地产信托","SMA":"Smartstop Self Storage REIT Inc"},"translate_title":"Entyvio在儿童溃疡性结肠炎试验中显示出强劲结果，显示出解决治疗差距的潜力，武田股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1,"SMA":1},"content_text":"Takeda Pharmaceutical Co Ltd (NYSE:TAK) shares are down on Friday morning as the company is reportedly demonstrating positive Phase 3 data for its drug Entyvio.\nThis news comes as the broader market experienced mixed performance, with the S&P 500 and Nasdaq both showing slight gains while the Dow Jones declined.\n      • What’s next for TAK stock?\nTakeda’s recent announcement highlights the potential of Entyvio (vedolizumab) to address treatment gaps for patients with ulcerative colitis and Crohn’s disease.\nTakeda released positive data from the pivotal Phase 3 KEPLER trial of Entyvio (vedolizumab) for patients aged between two and 17 years with moderately to severely active ulcerative colitis, a chronic inflammatory disease of the gastrointestinal tract.\nThe company reported that the drug demonstrated significant efficacy in clinical trials, which may prompt increased interest from investors and healthcare professionals alike.\nNearly half (47.3%) of participants achieved the primary endpoint of clinical remission at week 54.\nMore than one-third (34.7%) of patients achieved clinical remission at 14 weeks (secondary endpoint).\nGreater than 1 in 4 (29%) participants attained the secondary endpoint of sustained clinical remission at both weeks 14 and 54.\nThis positive outcome could enhance Takeda’s market position and drive further research and development investments.\nThe broader market experienced mixed performance on the previous trading day, with the Dow Jones falling by 0.24% while the S&P 500 and Nasdaq both gained marginally. Takeda’s stock movement aligns with the slight uptick in the health care sector, which remained stable despite the overall market’s fluctuations.\nCurrently, the stock is trading 1.5% above its 20-day simple moving average (SMA) and 3.2% above its 100-day SMA, indicating a positive short-term trend.\nOver the past 12 months, shares have increased by 12%, and they are currently positioned closer to their 52-week highs than lows, reflecting overall strength in the stock’s performance.\nThe RSI is at 50.00, which is considered neutral territory, suggesting the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating bearish pressure on the stock.\nThe combination of neutral RSI and bearish MACD suggests mixed momentum for Takeda’s shares.\nTAK Price Action: Takeda Pharmaceutical shares were down 0.64% at $18.55 at publication on Friday, according to Benzinga Pro data.\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}